Shattuck Labs

STTK · NASDAQ

$5.84+$0.47 (+8.75%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $5.37

STTK analyst rating

BuyConsensus of 10 analysts over the last 12 months. 100% rate it a buy.

Strong buy1
Buy9
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $15.56 (+166.4% upside)

Low: $10.10
Now: $5.84
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

STTK analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 12, 2026	Initiates	Buy	$17.00	0%
Wedbush	Oct 2, 2026	Maintains	Outperform	$11.00 → $14.00	46%
Needham	Oct 2, 2026	Maintains	Buy	$17.00 → $19.00	47%
Raymond James	Aug 24, 2026	Initiates	Strong Buy	$18.00	60%
HC Wainwright & Co.	Aug 11, 2026	Maintains	Buy	$18.00 → $14.00	40%
JP Morgan	Jul 24, 2026	Initiates	Overweight	$10.00	40%
Leerink Partners	Jul 20, 2026	Initiates	Outperform	$16.00	58%
Citigroup	Jun 9, 2026	Maintains	Buy	$7.00 → $18.00	42%
Needham	Jun 8, 2026	Maintains	Buy	$14.00 → $17.00	47%
HC Wainwright & Co.	Jun 8, 2026	Maintains	Buy	$18.00	40%

The case for and against

Updated Oct 14, 2026

Bull case

Shattuck Labs is attractive because SL-325 has a differentiated, selective DR3-targeting mechanism that is now being validated by Merck’s positive TL1A data in HS, while Shattuck’s own Phase 1 showed only a 3.7% ADA rate versus 48%-100% for anti-TL1A antibodies, supporting a stronger durability and safety profile. Management is broadening the program into multiple value-driving indications, with the Phase 2 RECEPTIVE-CD1 Crohn’s study on track to initiate in 3Q26 and the HS study planned later this year, which could materially expand the addressable market beyond IBD. Financially, existing cash is expected to fund operations into 2029, and the stock appears undervalued relative to the platform’s risk-adjusted potential, including quarterly maintenance dosing and a growing pipeline from SL-846.

Bear case

Shattuck Labs is a high-risk biotechnology name whose value is heavily dependent on SL-325 and related pipeline assets, yet those programs remain unproven and could fail on efficacy, immunogenicity, safety, or regulatory grounds. The company also faces intense competition in TL1A and inflammatory bowel disease, while manufacturing and commercialization hurdles could further limit uptake even if development succeeds. Financially, it is not expected to be profitable for several years and may need additional capital to fund lengthy clinical development, creating dilution and financing risk if market conditions are unfavorable.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.